The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom

In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objective was to determine the potential cost-effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli, Michele A., Maschio, Michael, Mould-Quevedo, Joaquin F., Drummond, Michael, Weinstein, Milton C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828088/
https://www.ncbi.nlm.nih.gov/pubmed/34550848
http://dx.doi.org/10.1080/21645515.2021.1971017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828088/
https://www.ncbi.nlm.nih.gov/pubmed/34550848
http://dx.doi.org/10.1080/21645515.2021.1971017

Ejemplares similares